236 related articles for article (PubMed ID: 28703720)
1. Therapeutic Drug Monitoring for Perampanel in Japanese Epilepsy Patients: Influence of Concomitant Antiepileptic Drugs.
Yamamoto Y; Usui N; Nishida T; Takahashi Y; Imai K; Kagawa Y; Inoue Y
Ther Drug Monit; 2017 Aug; 39(4):446-449. PubMed ID: 28703720
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics, tolerability, and clinical effectiveness of perampanel in Japanese patients with epilepsy.
Yamamoto Y; Shiratani Y; Asai S; Usui N; Nishida T; Imai K; Kagawa Y; Takahashi Y
Seizure; 2020 Dec; 83():181-186. PubMed ID: 33171342
[TBL] [Abstract][Full Text] [Related]
3. Perampanel Serum Concentrations in Adults With Epilepsy: Effect of Dose, Age, Sex, and Concomitant Anti-Epileptic Drugs.
Patsalos PN; Gougoulaki M; Sander JW
Ther Drug Monit; 2016 Jun; 38(3):358-64. PubMed ID: 26727625
[TBL] [Abstract][Full Text] [Related]
4. A Liquid Chromatography-Mass Spectrometry Assay for Determination of Perampanel and Concomitant Antiepileptic Drugs in the Plasma of Patients With Epilepsy Compared With a Fluorescent HPLC Assay.
de Grazia U; DʼUrso A; Ranzato F; De Riva V; Contarato G; Billo G; Perini F; Galloni E
Ther Drug Monit; 2018 Aug; 40(4):477-485. PubMed ID: 29746395
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and tolerability of adjunct perampanel based on number of antiepileptic drugs at baseline and baseline predictors of efficacy: A phase III post-hoc analysis.
Glauser T; Laurenza A; Yang H; Williams B; Ma T; Fain R
Epilepsy Res; 2016 Jan; 119():34-40. PubMed ID: 26656783
[TBL] [Abstract][Full Text] [Related]
6. Clinical profiles associated with serum perampanel concentrations in children with refractory epilepsy.
Ishikawa N; Tateishi Y; Tani H; Kobayashi Y; Kobayashi M
Epilepsy Behav; 2019 May; 94():82-86. PubMed ID: 30897534
[TBL] [Abstract][Full Text] [Related]
7. Concentration-effect relationships with perampanel in patients with pharmacoresistant partial-onset seizures.
Gidal BE; Ferry J; Majid O; Hussein Z
Epilepsia; 2013 Aug; 54(8):1490-7. PubMed ID: 23772853
[TBL] [Abstract][Full Text] [Related]
8. Changes in serum perampanel concentration profile after discontinuation of carbamazepine.
Murugesu S; Okayama K; Yamamoto Y; Terada K; Takahashi Y
Epileptic Disord; 2020 Aug; 22(4):455-461. PubMed ID: 32782230
[TBL] [Abstract][Full Text] [Related]
9. Influence of Inflammation on the Pharmacokinetics of Perampanel.
Yamamoto Y; Takahashi Y; Horino A; Usui N; Nishida T; Imai K; Kagawa Y; Inoue Y
Ther Drug Monit; 2018 Dec; 40(6):725-729. PubMed ID: 30086086
[TBL] [Abstract][Full Text] [Related]
10. Topiramate therapeutic monitoring in patients with epilepsy: effect of concomitant antiepileptic drugs.
Contin M; Riva R; Albani F; Avoni P; Baruzzi A
Ther Drug Monit; 2002 Jun; 24(3):332-7. PubMed ID: 12021622
[TBL] [Abstract][Full Text] [Related]
11. Lacosamide serum concentrations in adult patients with epilepsy: the influence of gender, age, dose, and concomitant antiepileptic drugs.
Markoula S; Teotonio R; Ratnaraj N; Duncan JS; Sander JW; Patsalos PN
Ther Drug Monit; 2014 Aug; 36(4):494-8. PubMed ID: 24562047
[TBL] [Abstract][Full Text] [Related]
12. Lacosamide therapeutic monitoring in patients with epilepsy: effect of concomitant antiepileptic drugs.
Contin M; Albani F; Riva R; Candela C; Mohamed S; Baruzzi A
Ther Drug Monit; 2013 Dec; 35(6):849-52. PubMed ID: 23942540
[TBL] [Abstract][Full Text] [Related]
13. Development and Validation of an HPLC-UV Assay for the Therapeutic Monitoring of the New Antiepileptic Drug Perampanel in Human Plasma.
Franco V; Marchiselli R; Fattore C; Tartara E; De Sarro G; Russo E; Perucca E
Ther Drug Monit; 2016 Dec; 38(6):744-750. PubMed ID: 27753779
[TBL] [Abstract][Full Text] [Related]
14. Usefulness of saliva for perampanel therapeutic drug monitoring.
Kim DY; Moon J; Shin YW; Lee ST; Jung KH; Park KI; Jung KY; Kim M; Lee S; Yu KS; Jang IJ; Song K; Chu K; Lee S
Epilepsia; 2020 Jun; 61(6):1120-1128. PubMed ID: 32378757
[TBL] [Abstract][Full Text] [Related]
15. Influence of uridine diphosphate glucuronosyltransferase inducers and inhibitors on the plasma lamotrigine concentration in pediatric patients with refractory epilepsy.
Yamamoto Y; Takahashi Y; Imai K; Ikeda H; Takahashi M; Nakai M; Inoue Y; Kagawa Y
Drug Metab Pharmacokinet; 2015 Jun; 30(3):214-20. PubMed ID: 25825021
[TBL] [Abstract][Full Text] [Related]
16. Perampanel efficacy and tolerability with enzyme-inducing AEDs in patients with epilepsy.
Gidal BE; Laurenza A; Hussein Z; Yang H; Fain R; Edelstein J; Kumar D; Ferry J
Neurology; 2015 May; 84(19):1972-80. PubMed ID: 25878177
[TBL] [Abstract][Full Text] [Related]
17. The clinical pharmacology profile of the new antiepileptic drug perampanel: A novel noncompetitive AMPA receptor antagonist.
Patsalos PN
Epilepsia; 2015 Jan; 56(1):12-27. PubMed ID: 25495693
[TBL] [Abstract][Full Text] [Related]
18. Long-term tolerability, safety and efficacy of adjunctive perampanel in the open-label, dose-ascending Study 231 and extension Study 233 in Japanese patients with epilepsy.
Usui N; Akamatsu N; Nakasato N; Ohnishi A; Kaneko S; Hiramatsu H; Saeki K; Miyagishi H; Inoue Y
Seizure; 2018 Nov; 62():26-32. PubMed ID: 30267941
[TBL] [Abstract][Full Text] [Related]
19. Analysis of pooled phase III trials of adjunctive perampanel for epilepsy: Impact of mechanism of action and pharmacokinetics on clinical outcomes.
Kwan P; Brodie MJ; Laurenza A; FitzGibbon H; Gidal BE
Epilepsy Res; 2015 Nov; 117():117-24. PubMed ID: 26448264
[TBL] [Abstract][Full Text] [Related]
20. Effect of valproic acid on perampanel pharmacokinetics in patients with epilepsy.
Contin M; Bisulli F; Santucci M; Riva R; Tonon F; Mohamed S; Ferri L; Stipa C; Tinuper P;
Epilepsia; 2018 Jul; 59(7):e103-e108. PubMed ID: 29897632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
